Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02721979 · ClinicalTrials.gov registry record · Phase 2
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02721979 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 24 participants.
The verdict
NCT02721979, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Apalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02721979
The ClinicalTrials.gov registry entry for NCT02721979 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02721979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02721979 about?
NCT02721979 is a clinical study titled "Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance". This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate cancer by blocking the use of...
What is the current status of trial NCT02721979?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2017-11-02. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT02721979?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Apalutamide (DRUG).
Who is sponsoring clinical trial NCT02721979?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.